05). The changes of COX-2 positive expression were associated with the survival time and survival rate (p<0.05) in patients with NPC following treatment. T stage, COX-2 expression before treatment and changes in COX-2 expression after treatment were independent factors affecting NPC prognosis (p<0.05).
 
  Changes in COX-2 expression levels before and after treatment may be a useful indicator for assessing the prognosis of NPC after chemoradiotherapy.
 Changes in COX-2 expression levels before and after treatment may be a useful indicator for assessing the prognosis of NPC after chemoradiotherapy.
  Eriodictyol is an active flavonoid present in several vegetables and fruits. Eriodictyol-bearing plants have long been used in folk medicine used to treat different human disorders. It has been reported to exhibit the anticancer, antioxidative and antiinflammatory properties. The current research study was designed to explore the anticancer potential of eriodictyol against CNE1 nasopharyngeal cancer (NP) cells. Additionally, its effects of targeting MEK/ERK signalling pathway, autophagy, cell migration and invasion were also examined.
 
  MTT assay was applied for viability measurements, and clonogenic potency measurements were made by clonogenic assay. Autophagy was monitored by transmission electron microscopy (TEM). Cell migration capability was examined by wound healing assay, and transwell chambers assay was used for estimation of cell invasion. Western blotting assay was performed to examine protein expression levels.
 
  The results indicated the proliferation rate of CNE1 cells was reduced in eriodictyol dose-dependently. Cell colonies were also observed to be minimised after eriodictyol exposure. The underlying mechanism of antiproliferative effects of eriodictyol in the current research was found to be autophagy-mediated as suggested by TEM and increased expressions of pro-autophagy proteins. Cell migration and invasion was significantly suppressed by eriodictyol in CNE1 cells. Finally, western blotting assay indicated that eriodictyol blocked MEK/ERK signalling pathway dose-dependently.  https://www.selleckchem.com/products/pu-h71.html  In conclusion, the results of the currently performed investigation indicated that eriodictyol is a potential anticancer agent against CNE1 nasopharyngeal cancer.
 
  Therefore, this molecule may prove a leading agent in nasopharyngeal cancer treatment provided further in vitro and in vivo investigations are performed.
 Therefore, this molecule may prove a leading agent in nasopharyngeal cancer treatment provided further in vitro and in vivo investigations are performed.
  To evaluate the efficacy and safety of self-retaining laryngendoscope-assisted low-temperature plasma ablation (LTPA) in the treatment of patients with early glottic cancer.
 
  The clinical data of 84 patients with early glottic cancer treated in our department from May 2013 to May 2016 were collected. All patients were divided into the Plasma group (n=42, treated with the laryngendoscopic LTPA) and the Laryngofissure group (n=42, treated with traditional laryngofissure). The operation conditions, pain and cough visual analogue scale (VAS) scores, postoperative complications, mucosal recovery and voice recovery indexes were compared between the two groups, the postoperative recurrence rate was recorded, and the patients were followed up for tumor recurrence and survival.
 
  In the Plasma group, the operation time was significantly shorter than that in the Laryngofissure group, the amount of intraoperative bleeding was significantly less than that in the Laryngofissure group (p<0.001), and the postoperativeg laryngendoscope-assisted LTPA has definite efficacy in the treatment of early glottic cancer, after which the recurrence rate and survival rate are similar to those after open laryngofissure, but LTPA is characterized by short operation time, less postoperative bleeding, quick recovery of patients and better voice recovery.
  Long non-coding RNA (lncRNA) prostate cancer-associated transcripts 1 (PCAT1) is a noticeable lncRNA involved in the tumorigenesis of various cancers. Nowadays, the biological function of PCAT1 on the stemness of non-small cell lung cancer (NSCLC) is still unclear. Our purpose was to explore the molecular mechanism of PCAT1 and its target protein in advanced NSCLC.
 
  The levels of PCAT1 and Fyn-related kinase (FRK) in NSCLC tissues and cell lines were evaluated by quantitative polymerase chain reaction (qPCR). The log-rank test was applied to evaluate the role of high PCAT1 levels in shortening the overall survival of NSCLC patients. Chi-square test was to assess the relation between PCAT1 expression and clinicopathological features of NSCLC patients. CCK8 assay tested the cell proliferation of NSCLC cells with PCAT1 overexpression. The underlying regulatory mechanism between PCAT1 and Fyn-related kinase (FRK) was predicted by bioinformatics and verified by RNA transfection, qPCR, and western blotting. Chro useful target for intervention in NSCLC.
 GATA6/PCAT1 may markedly maintain the stemness of NSCLC, resulting in late TNM stage and poor survival. These findings suggest that the GATA6-PCAT1-FRK axis may be a useful target for intervention in NSCLC.
  To explore the efficacy and safety of docetaxel/cisplatin concurrent chemoradiotherapy (CCRT) combined with dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy in the treatment of locally advanced non-small cell lung cancer (LANSCLC).
 
  The clinical data of 142 LANSCLC patients treated in our hospital from March 2014 to March 2016 were retrospectively analyzed. 71 patients were treated with docetaxel/cisplatin CCRT (CCRT group), while the remaining 71 patients underwent CCRT combined with DC-CIK immunotherapy (DC-CIK group). The clinical data of all patients were collected, the short-term efficacy, the changes in serum immunological indexes and quality of life before and after treatment, and the incidence of adverse reactions were compared between the two groups, and the overall survival (OS) and progression-free survival (PFS) were recorded during the follow-up of patients.
 
  After treatment, the level of cluster of differentiation 3+ (CD3+) CD4+ T lymphocytes, CD4/CD8 ratio and CD56+ natural killer (NK) cell ratio significantly rose, while the level of CD3+ CD8+ T lymphocytes significantly declined in both groups compared with those before treatment.